Transforming Commercial Pharma with Agentic AI

The Next Frontier: Transforming Commercial Pharma with Agentic AI

Sign up for the whitepaper and learn how Agentic AI is set to disrupt pharma’s commercial engagement - and why acting now is key to staying ahead. Explore how a strategic approach to AI adoption can help pharma scale impact, optimize operations, and unlock lasting value.

Read more
filters
AI Transformation
Customer Engagement & Experience
Personalization at Scale
Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

Key Challenges Addressed
  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed
  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed
  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed

  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed

  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed

What You’ll Discover in the Whitepaper
  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper
  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper
  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper

  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper

  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Whitepaper

AI in pharma is moving beyond support tools to autonomous agents that transform engagement end-to-end. In this whitepaper, we explore the next frontier of Agentic AI - what it means for customer engagement, how to scale it responsibly, and the steps pharma companies must take today to stay ahead. Sign up to receive the full whitepaper and get practical guidance on turning AI potential into measurable business impact.

Interested in exploring how agnetic AI apply in your context?

Feel free to reach out for a deeper discussion.

Managing Director, Intellishore CH
Mikkel Møller Andersen

Managing Director, Intellishore CH
Mikkel Møller Andersen
Mikkel Møller Andersen
This is the default text value
Head of AI
Peter Nistrup

Head of AI
Peter Nistrup
Peter Nistrup
This is the default text value
Senior Manager - Intellishore CH
Rebecca Bub

Senior Manager - Intellishore CH
Rebecca Bub
Rebecca Bub
This is the default text value
filters
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Rethinking Data Governance as a Business-Led Discipline

In this article, we outline why effective data governance starts with ownership, not tools - and how organizations can build the structures that make data trustworthy and scalable.

Click to read more
Data Governance
Rethinking Data Governance as a Business-Led Discipline
Rethinking Data Governance as a Business-Led Discipline
AI Transformation
The New Era of Life Sciences Will Be Won on Forecasting Excellence

In this article, we explore why the blockbuster era is giving way to a more fragmented, competitive landscape - and how machine learning is changing the way life science companies predict erosion, time investments, and launch with precision.

Click to read more
Drivers-Based ML forecasting
The New Era of Life Sciences Will Be Won on Forecasting Excellence
The New Era of Life Sciences  Will Be Won on Forecasting Excellence
Forecasting & Scenario Planning
Global to Local Content Excellence

In this article we give our point of view on how healthcare organizations can design a scalable content engine with local flexibility for impactful customer engagement - and how to succeed where other organizations typically fail.

Click to read more
Content Excellence
Global to Local Content Excellence
Global to Local Content Excellence
Customer Engagement & Experience
Personalization at Scale
The Build vs Buy Dillemma: Balancing correctness and differentiation in enterprise AI

In this perspective on Build vs Buy in AI, we share how to move beyond a buy-only mindset by designing AI around your processes and competitive edge. We explore why off-the-shelf works well in domains where correctness and compliance matter most, why you need more ownership in use cases that drive differentiation, and how a hybrid approach - buying the base and building the system around it - keeps operations stable while still enabling you to stand out.

Click to read more
AI STRATEGY
The Build vs Buy Dillemma
The Build vs Buy Dillemma
AI Transformation